

addition of claim 10 can be found in column 3, lines 53-56 of the specification. Specifically, line 56 states that the “C-terminus **may be amidated**” (emphasis added). Thus, the C-terminus of this peptide may contain either a free carboxyl group or may contain an amide group. Claims 1 and 8 of the reissue application are directed to the peptide which contains an amide group. New claim 10 is being added so that a claim is directed to the peptide which contains a free carboxyl group. New claim 11 is supported at line 56 of column 3 of the specification where it is stated that the “Thr may be glycosylated.”

In addition to this specific support for new claims 10 and 11, Applicants note that at column 3, lines 28-33 of the reissue specification the peptide J-029 is disclosed. According to this passage the C-terminus of the peptide (SEQ ID NO:7) “**may optionally be amidated**” (emphasis added). Claims 1 and 2 directed to this peptide, claim the peptide without an amidated C-terminus, i.e., the C-terminus has a free carboxyl group. It is believed that this passage supports a peptide which contains a free carboxyl group or an amide group at the C-terminus, just as the passage with respect to SEQ ID NO:13 (peptide J-004) supports a peptide which contains a free carboxyl group or an amide group. Thus, it is believed that the disclosure at column 3 of the reissue application with respect to the peptides J-029 and J-004 supports claims to these peptides with a free carboxyl group. Consequently, it is believed that new claims 10 and 11 are fully supported by the specification of the resissue application.

It is believed that these new claims do not constitute new matter and their entry is requested.

Respectfully submitted,

By 

Jeffrey L. Ihnen

Attorney for Applicants

Registration No. 28,957

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 701-E, 555 13th Street, N.W.

Washington, D.C. 20004

Telephone: (202)783-6040